CELLTRION
Celltrion partners with TV star Mollie Pearce to launch the second installation of the Where’s Crohn’s & Colitis (CC)? campaign for this year’s World IBD Day (19 May 2024).
The campaign focuses on access to IBD care and treatment as the burden of the condition rises globally1. Widening inequalities and significant variations in access across the globe, and even within countries, is impacting people’s experience of IBD care and ultimately their outcomes2.
Through raising awareness of the factors driving these inequalities and potential solutions, the campaign hopes to encourage improved access to a timely diagnosis, high quality care and innovative treatments.
Innovations in treatments, including advances in treatment administration that enable people to access at-home injectable treatment (versus hospital-based treatment), allows people to have an improved quality of life whilst managing their condition3.
The campaign encourages people to look beyond what they would usually see, to make the invisible condition, visible. In doing so, users are taken on a journey across borders to explore inequalities in IBD at a global scale and how these could be overcome.
Reality TV star Mollie Pearce, a contestant on the popular UK show ‘The Traitors’, partners with Celltrion to launch the campaign. Mollie was diagnosed with UC when she was 11 years old and has openly shared her experiences living with the disease as an advocate for the IBD community, breaking down stigma and inspiring others to seek the care that works best for them.
Mollie Pearce, media personality and finalist on ‘The Traitors’, commented: “Living with a condition such as UC comes with so many challenges - from sometimes not being able to leave the house to missing out on social occasions with friends. That’s why I’m so passionate about being an advocate for the IBD community and helping others to break down barriers and do the things they never thought were possible once they were diagnosed.
“The Where’s CC? campaign is really close to my heart. I want to do all I can to ensure everyone is treated as an individual and gets the care they deserve.”
Mr. Kevin Byoung Seo Choi, Executive VP and head of the marketing division at Celltrion, said: “It is simply unacceptable that there are so many barriers in accessing IBD care. From geographic disparities in access to infusion centers to health system limitations and education, there is an urgent need to tackle the root cause of inequalities globally so that all patients can access potentially life-changing therapies.
“We are committed to tackling inequalities and ensuring a sustainable future for all IBD patients. The Where’s CC? campaign is our latest step in making this a reality through raising awareness and advocating for change.”
The first instalment of the Where’s CC? campaign, launched for World IBD Day 2023, focused on age-related inequalities in IBD, and how the challenges that come with the condition can vary at different stages of life.
Visit www.WhereisCC.com to learn more about the Where’s CC? campaign and inequalities in access to care and treatment in IBD, and how these can be overcome to improve IBD outcomes for all.
World IBD Day is an annual awareness campaign led by patient organisations representing over 50 countries on five continents and coordinated by the European Federation of Crohn’s and Ulcerative Colitis Associations (EFCCA)4.
ABOUT INFLAMMATORY BOWEL DISEASE (IBD)
IBD is an umbrella term used to describe conditions including Crohn’s disease and ulcerative colitis. Collectively, IBD impacts over 10 million people worldwide with incidence rates rapidly increasing across the world5.
IBD is a long-term condition and there may be times when the symptoms are severe, known as a flare-up, and times when there are no or few symptoms, known as remission. Common symptoms of IBD include pain, cramping or swelling in the stomach, episodes of diarrhoea, weight loss and extreme tiredness6. IBD can appear for the first time at any age, however, diagnosis most commonly takes place between the ages of 10 and 405.
Treatment for IBD can be transformative for patients’ lives, reducing the impact of the condition on their lives by minimising flare-ups and maintaining remission. In recent years, the increasing availability of new treatments has transformed IBD patient care.
ABOUT ‘THE TRAITORS’
‘The Traitors’ is a British reality TV series involving a group of players who are seemingly focused on a common goal – the ‘faithfuls’ must eliminate all the ‘traitors’ from the group. Mollie Pearce appeared in Series Two of the programme, making it to the final where she cast the deciding vote of the series.
ABOUT CELLTRION
Celltrion is a leading biopharmaceutical company that specializes in research, development and manufacturing of innovative therapeutics that improve people's lives worldwide. The company’s portfolio of anti-TNF therapies spans a number of indications across distinct therapy areas: immunology, hemato-oncology and ophthalmology. We are dedicated to expanding patient access to life-changing biologic therapies while generating healthcare sustainability with meaningful cost savings for patients worldwide. To learn more, please visit www.celltrion.com/en-us.
FORWARD-LOOKING STATEMENT
Certain information set forth in this press release contains statements related to our future business and financial performance and future events or developments involving Celltrion/Celltrion Healthcare that may constitute forward-looking statements, under pertinent securities laws.
These statements may be identified by words such as “prepares”, “hopes to”, “upcoming”, ”plans to”, “aims to”, “to be launched”, “is preparing, “once gained”, “could”, “with the aim of”, “may”, “once identified”, “will”, “working towards”, “is due”, “become available”, “has potential to”, the negative of these words or such other variations thereon or comparable terminology.
In addition, our representatives may make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Celltrion/Celltrion Healthcare's management, of which many are beyond its control.
Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them.
Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.
Although forward-looking statements contained in this presentation are based upon what management of Celltrion/Celltrion Healthcare believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Celltrion/Celltrion Healthcare undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.
References
1 The Lancet Gastroenterology & Hepatology. Promoting equity in inflammatory bowel disease: a global approach to care. Available at: https://www.thelancet.com/journals/langas/article/PIIS2468-1253(23)00368-0/abstract#back-bib4 [Accessed: May 2024]
2 Journal of Crohn’s and Colitis. P018 Inequalities in healthcare access, experience and outcomes in adults with Inflammatory Bowel Disease: A scoping review. Available at: https://academic.oup.com/ecco-jcc/article/18/Supplement_1/i269/7586146 [Accessed: May 2024]
3 BMC Proceedings. Intravenous versus subcutaneous delivery of biotherapeutics in IBD: an expert’s and patient’s perspective. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8654488/#:~:text=Benefits%20of%20the%20subcutaneous%20application%20of%20drugs%20include,are%20able%20to%20administer%20their%20treatments%20at%20home. [Accessed: May 2024]
4 EFCCA. World IBD Day. Available at: https://worldibdday.org/ [Accessed: May 2024]
5 EFCCA. What is IBD? Available at: https://efcca.org/content/what-ibd [Accessed: May 2024]
6 NHS. Inflammatory bowel disease. Available at: https://www.nhs.uk/conditions/inflammatory-bowel-disease/ [Accessed: May 2024]
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240517193492/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LambdaTest and SVAM International Inc. Announce Partnership to Transform Quality Engineering for Businesses26.11.2025 18:00:00 CET | Press release
The alliance empowers enterprises with accelerated SDLC cycles, reduced testing effort, and modern AI-driven digital transformation capabilities LambdaTest, a Gen-AI native quality engineering platform, announced a partnership with SVAM International, Inc., a global leader in digital transformation services. This strategic alliance marks a significant step forward in their mission to transform quality engineering for businesses worldwide. The partnership allows LambdaTest to extend its AI-native quality engineering capabilities into SVAM’s extensive digital transformation ecosystem. By integrating with SVAM’s experience in large-scale application development, testing, and delivery across major New York State and City agencies, as well as their platform expertise across Salesforce, ServiceNow, and Dynamics365, LambdaTest will empower more enterprises to modernize their software delivery pipelines. With LambdaTest’s intelligent test orchestration and execution engine at the core, teams c
GLORY Acquires Remaining Equity Shares in Acrelec Group26.11.2025 16:11:00 CET | Press release
Acrelec becomes a wholly owned subsidiary of Glory Glory Global Solutions (International) Ltd, a wholly-owned subsidiary of GLORY Ltd. [TYO:6457], has announced the acquisition of the remaining equity shares in Acrelec Group SAS. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251126039437/en/ Acrelec is a global technology company focused on reinventing the customer experience for restaurant and retail brands. Leveraging decades of software, hardware and service expertise, the company develops and integrates new platforms that increase customer engagement, optimize efficiency and improve operations. With over 120,000 installations across more than 70 countries, Acrelec counts many of the world’s best-known restaurant mega-brands among its customers. We announce that Jalel Souissi has left the Acrelec Group following the completion of the recent share acquisition. Jalel Souissi has played a pivotal role in the development and
Andersen Global styrker sin platform i Tyrkiet med tilføjelsen af medlemsvirksomhed26.11.2025 14:49:00 CET | Pressemeddelelse
Andersen Global udvider sin tilstedeværelse i Tyrkiet, efter at Celen Corporate Property Valuation & Counseling Inc. bliver til Andersen i Tyrkiet, hvilket udvider de kompetencer, der tilbydes under Andersen-brandet i landet. Det Istanbul-baserede firma blev stiftet i 1995 og ledes af Managing Partner Guniz Celen med en bred vifte af ydelser til både nationale og internationale kunder. Med ekspertise inden for finansiering af fast ejendom, værdiansættelse af materielle og immaterielle aktiver samt formueforvaltning leverer den tyrkiske afdeling af Andersen løsninger, der understøtter komplekse finansielle beslutninger for kunder i mere end 18 lande. “Vores mission har altid været at levere løsninger på de mest komplekse udfordringer inden for ejendoms- og investeringssektoren,” sagde Guniz. “At blive en del af Andersen-brandet styrker vores kompetencer som en betroet rådgiver og giver os adgang til globale ressourcer, hvilket gør os i stand til at skabe endnu større langsigtet værdi fo
Cegid Acquires Shine to Accelerate the Path of Becoming Europe's Leading Financial Copilot for SMBs and Accountants26.11.2025 14:00:00 CET | Press release
Transformative combination creates a powerhouse for SMBs and accountants, empowering businesses across Europe by integrating leading suites of e-invoicing, digital accounting, business accounts and payments, and HR solutions into a unified platform. Cegid, a European leader in cloud software for finance, accounting, HR, and retail software, and Shine, a fast-growing European fintech unicorn providing digital business accounts and payments, e-invoicing, accounting, and payroll software to small businesses across Europe, announced today that the companies have entered a definitive agreement to join forces to form a European champion and become a leading provider of software for businesses and their accountants. This transformational combination will create the first fully integrated, cloud-native and AI-driven financial hub for SMBs and accounting professionals in Europe – bringing together market-leading capabilities in e-invoicing, accounting, digital business accounts and payments, ta
U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma26.11.2025 12:00:00 CET | Press release
If approved, sonrotoclax will become the first BCL2 inhibitor for R/R MCL in the U.S., addressing a high unmet need in an aggressive cancerSonrotoclax previously received Breakthrough Therapy Designation based on clinically meaningful, rapid responses in R/R MCLBeOne Medicines will present the data supporting the NDA and Priority Review for the first time at ASH 2025 BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to a New Drug Application (NDA) for sonrotoclax, a next-generation BCL2 inhibitor, for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase (BTK) inhibitor. “Sonrotoclax is advancing with remarkable speed, from Breakthrough Therapy Designation to Priority Review, all within a short window,” said Lai Wang, Ph.D., Global Head of R&D at BeOne.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom